Know Cancer

forgot password

A Multicenter Clinical Study of the Sonablate® 500 (SB-500) for the Treatment of Localized (T1c/T2a) Prostate Cancer With HIFU

40 Years
75 Years
Open (Enrolling)
Prostate Cancer

Thank you

Trial Information

A Multicenter Clinical Study of the Sonablate® 500 (SB-500) for the Treatment of Localized (T1c/T2a) Prostate Cancer With HIFU

The proposed study is a prospective, non-randomized concurrently controlled study. The
active treatment arm uses the HIFU procedure with the Sonablate device. The control arm uses
the brachytherapy procedure. The safety and effectiveness of the Sonablate arm will be
compared with the brachytherapy arm. The control arm of the study will be conducted at
clinical sites different from the Sonablate arm.

Inclusion Criteria:

- T1c or T2a carcinoma of the prostate confirmed by biopsy;

- life expectancy of 5(five) years or more;

- prostate biopsy with 10(ten) or more core biopsies;

- Gleason score of 6(six) or less;

- serum Prostate Specific Antigen (PSA) of 10(ten)ng/ml or less;

- prostate volume of less than 40(Forty)cc;

- distance from the Anterior capsule surface to the Posterior capsule surface (AP
Diameter) of 40(Forty)cm or less;

- informed consent for the treatment study through 24 months post-treatment follow-up

Exclusion Criteria:

- men who have had previous definitive treatment for prostate cancer;

- evidence of metastatic disease and/or a previous positive bone-scan, previous
diagnosis or treatment for cancer within the last 5(five) years;

- prior hormonal therapy for prostate cancer (including bilateral orchiectomy);

- inability to tolerate a transrectal ultrasound;

- active urinary tract infection;

- functional bladder problems;

- prior significant rectal surgery;

- intra-prostatic calcifications greater than 1(One)cm in diameter;

- interest in future fertility;

- prostatic surgery/procedure (except biopsy) within 1(One) year;

- large median lobe of the prostate;

- use of medications that can affect PSA within 2(Two) months (e.g. finasteride, saw

- current bladder cancer, urethral stricture, or bladder neck contracture;

- urinary tract and/or rectal fistula;

- rectal fibrosis/stenosis;

- anomaly of the rectal anatomy or mucus membrane;

- prostate seroma/abcess;

- prostatitis;

- compromised renal function or upper urinary tract disease secondary to urinary

- bleeding disorders/coagulopathy based on measures of PT and PTT;

- implant in the prostate or within 1(One)cm of the prostate;

- zip code of the primary residence of the subject is greater than 200(Two hundred)
miles from the clinical site or transportation that would hinder the completion of
the study

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

The primary endpoint will be the absence of biochemical failure, which is defined as a rise of 2.0 ng/mL or more above the PSA nadir and negative biopsy at 24 months.

Outcome Time Frame:

24 Months

Safety Issue:


Principal Investigator

Mark Schoenberg, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Johns Hopkins Medical Institution


United States: Food and Drug Administration

Study ID:




Start Date:

April 2007

Completion Date:

December 2013

Related Keywords:

  • Prostate Cancer
  • Primary
  • Prostate
  • Cancer
  • Primary T1c/T2a organ confined prostate cancer
  • organ-confined
  • Prostatic Neoplasms



Brachytherapy Site: Urology Centers of AlabamaBirmingham, Alabama  35209
Brachytherapy Site: Specialists in UrologyNaples, Florida  34102
Brachytherapy Site: Grand Strand UrologyMyrtle Beach, South Carolina  29572
HIFU Site: Southeast Urology NetworkMemphis, Tennessee  38119
HIFU Site: Urology AssociatesNashville, Tennessee  37209
HIFU Site: Urology of San AntonioSan Antonio, Texas  78229